Antimicrobial nanosurfaces for medical devices
Orthobond is the product of over a decade of research, experimentation, collaboration, and persistence. Our original platform technology was first developed at Princeton University, with the intention of improving the performance of medical devices.
Initially, our interest was in creating device surfaces that would enhance osteoconductivity. However, in response to requests from our industry partners, we eventually pivoted to focus on developing antimicrobial nanosurfaces for medical devices.
Today, the issue of medical device contamination is becoming more widely recognized as a leading cause of device failure. In light of new data presented by recent studies and improved methods for detecting occult infection, researchers now estimate that the number of patients affected globally by medical device-related infections has been grossly underestimated.
Medical complications resulting from an infected medical device are serious, ranging from mild or severe pain, at best, to revision surgery, amputation, and/or death in more severe cases. Despite the implementation of improved air flow handling in ORs, guidance from the CDC on infection prevention, and the widespread adoption of double gloving and routine glove changes in orthopaedic surgery, the infection problem has remained and continues to grow.
With the emergence of antibiotic-resistant organisms and the rising rate of revision surgeries, the need for preventative measures is greater than ever.
Orthobond has developed a suite of proprietary, non-eluting, antimicrobial nanosurfaces for medical devices with applications in orthopedics, trauma, cardiovascular, plastic surgery, dental, oncology, and ancillary industries. Our technology can be successfully applied to the majority of biomaterials used in the medical device industry.
The literature suggests that there is a threshold level of bacterial contamination on a medical device, above which the chance for an infection is greatly increased. Orthobond’s antimicrobial nanosurface technology works by killing unwanted microbes on the surfaces of medical devices, thereby reducing the risk for microbial contamination.
Our technology has been shown in both in vitro and in vivo studies to dramatically reduce microbial contamination of medical-grade surfaces, successfully killing a wide range of microorganisms that are commonly found at the site of infected medical devices.
Today, Orthobond is proud to announce that our treatment process is in its final stages of development toward commercialization.
Orthobond’s platform technology enables our team to covalently or chemically bind molecules that can enhance the performance of implantable medical devices and surgical tools. Although we are currently focused on antimicrobials, Orthobond’s technology can be used to bind many other end groups. Orthobond customizes partners’ surfaces by matching substrates with specific end group molecules to elicit the desired biological response.
We look forward to continuing to work with companies that are committed to improving the performance and safety of their devices, for the benefit of patients, hospitals, payors, and industry. In the process, we anticipate that our partners will gain a significant competitive advantage.
Driving innovation at the nanoscale to improve lives on a global scale
Orthobond is powered by a dedicated team of researchers, scientists, and business leaders striving to improve patient care by developing breakthrough technologies for the medical device industry.
Meet the team that’s driving medical device innovation at the nanoscale.
Board of Directors
Gregory E. Lutz, M.D.
With more than 25 years of clinical experience at the forefront of orthopedic medicine, Dr. Gregory E. Lutz has demonstrated a lifelong commitment to improving patient care by delivering innovative treatments and technologies to patients. Since co-founding Orthobond, Dr. Lutz has spent more than a decade advising and supporting research and development efforts with the goal of improving Orthobond’s nanosurface solutions to better address the growing unmet need for antimicrobial medical devices.
Prior to his involvement with Orthobond, Dr. Lutz founded the Physiatry Department at Hospital for Special Surgery and served as Physiatrist-in-Chief for 15 years, helping the department grow to become one of the largest and most successful outpatient musculoskeletal practices in the world.
In addition to his role at Orthobond, Dr. Lutz is currently the Physiatrist-In-Chief Emeritus at Hospital for Special Surgery and a Clinical Professor of Rehabilitation Medicine at Weill Medical College of Cornell University. He is also the Medical Director of the Regenerative SportsCare Institute in Manhattan.
Dr. Lutz graduated from Georgetown University School of Medicine in 1988, before completing his Physical Medicine & Rehabilitation Residency and Orthopedic Sports Medicine Fellowship at the Mayo Clinic and Hospital for Special Surgery, respectively, in the 1990s.
Peter K. Scaturro
Since retiring from Goldman Sachs, Mr. Peter K. Scaturro has focused on board positions and investing.
Mr. Scaturro joined Goldman Sachs as a partner to oversee the Global Wealth Management Business immediately following the sale of U.S. Trust to Bank of America. During his tenure, he was a member of the firm-wide Goldman Sachs Business Practices Committee and served on the Investment Management Division Operating Committee.
Before joining Goldman Sachs, Mr. Scaturro was chief executive officer of U.S. Trust, a position he assumed in 2005. While at U.S. Trust, Mr. Scaturro was a member of the Executive Committee of Charles Schwab. Mr. Scaturro left U.S. Trust after the successful sale of U.S. Trust to Bank of America for $3.3B.
From 1999 to 2004, Mr. Scaturro was the chief executive officer of the Citigroup Global Private Bank, responsible for the Private Bank’s 98 offices in 38 countries. He was a member of Citigroup’s Management Committee from 2002 to 2004. From 1986 to 1999, Mr. Scaturro worked at Bankers Trust, where he became a partner in 1998.
Mr. Scaturro holds graduate and undergraduate degrees in engineering from Columbia University and serves on the boards of several for-profit and not-for-profit organizations.
Lisa D’Urso, M.B.A.
Ms. Lisa D’Urso is a private investor focused on early stage companies in the biotechnology and food and beverage spaces. She is also active in real estate management. Ms. D’Urso brings a broad range of business experience to Orthobond’s board of directors, having advised and served on the boards of several privately-held companies and charitable concerns.
Previously, Ms. D’Urso served as a business and investment manager for a private concern, in which position she analyzed and invested in a wide range of private and publicly-traded companies and managed a real estate portfolio.
Prior to her career as an investor, manager and advisor, Ms. D’Urso was a Senior Executive for a New York supermarket operation, where she ultimately co-led in devising the structure and negotiation of the company’s sale.
Ms. D’Urso graduated from Georgetown University and received an M.B.A. in finance and economics from New York University’s Stern School of Business.
David L. Nichols
Mr. David Nichols is an industry veteran CEO who has held executive leadership roles at three Fortune 500 medical device companies: Zimmer Biomet, Synthes Spine, and United States Surgical. Over the course of his career, Mr. Nichols has led R&D for three successful startups, resulting in exits to large medical device companies totaling ~$400M.
Mr. Nichols is a proven leader in the orthopedic medical device space with a history of building and developing high-performance teams. He has extensive experience providing strategic and tactical direction, cultivating new markets, and delivering sustained growth in technology, revenue, and shareholder value—at both large and small organizations. Prior to joining Orthobond in 2020, Mr. Nichols served as the General Manager for Zimmer Biomet’s $200M Early Intervention Division. Under Mr. Nichols’ leadership, the Early Intervention Division led Zimmer Biomet’s growth in 2019 with 18% overall revenue growth. Mr. Nichols formerly served as Vice President & General Manager of Zimmer Knee Creations, where he expanded release of the company’s Subchrondroplasty® portfolio to key international markets and achieved significant product adoption within 38 of the top 50 orthopedic hospitals in the U.S, earning his division the accolade “Business Unit of the Year.”
Previously, as Senior Vice President of Research and Development at Knee Creations, Mr. Nichols led the development of the world’s first subchondroplasty system to treat subchondral bone lesions. At Knee Creations, Mr. Nichols provided executive leadership in partnership with the company’s CEO to develop a surgeon’s innovative idea into a clinically effective product and successful business that was ultimately acquired by Zimmer at an 8x revenue multiple. Before joining Knee Creations, Mr. Nichols was Vice President of Product Development at Synthes Spine, where he strategically led Synthes’ global spine portfolio to move from the third position to the second position in industry market share.
Mr. Nichols obtained his BSME in Mechanical Engineering from The University of Memphis, where he also pursued graduate studies in Mechanical Engineering and Operations Management. He has been an inventor on 46 medical device patents.
Mr. Khalil Barrage is a Managing Director and Global Head of Public Equity at The Invus Group, a global investment firm with over $5 billion under management.
Mr. Barrage joined Invus in 2003 and established its Public Equity Group, which he has led for the past 15 years. Since its inception, Invus Public Equity has concentrated its investments in the emerging biotech space, focusing on innovative companies with transformative technology and dedicated leadership.
Mr. Barrage follows a value discipline in selecting securities, focusing on out-of-favor stocks that are trading below their intrinsic value. Prior to joining Invus, he worked at The Olayan Group in New York and ran their U.S. Equity Portfolio for 15 years.
In addition to his advisory role at Orthobond, Mr. Barrage is a member of the boards of Protagenic Therapeutics, the Children of Armenia Fund, and Solving Kids’ Cancer. He holds a Bachelor’s degree in Economics from the American University of Beirut.
Ken Gall, Ph.D.
Professor Ken Gall is currently the Associate Dean of Entrepreneurship and Professor of Mechanical Engineering and Materials Science at Duke University. In addition, he is a Professor of Orthopaedic Surgery and the Associate Director of MEDx, a joint initiative between the School of Medicine and the Pratt School of Engineering that aims to accelerate the development of innovative solutions to complex clinical problems by fostering interdisciplinary collaboration among physicians, engineers, computer scientists, and researchers. Dr. Gall’s expertise is in the mechanical behavior of materials, with emphasis on the creation, modification, understanding, and commercialization of synthetic biomaterials. His publications have been cited over 18,000 times, with an H-index of 74.
Dr. Gall brings a unique blend of industry and academic experience to Orthobond’s board of directors and has a proven track record in the medical device space. He is a Founder and Director of four medical device start-ups based on new biomaterials (MedShape, Vertera, Restor3d, and Lacuna) whose implants have been implanted in nearly 100,000 patients worldwide. Dr. Gall is also a Director in three other early stage medical device companies (DeepBlue, InnAVasc, and Kinos). MedShape is now a fully functioning medical device company developing implants for foot and ankle reconstruction based on shape memory materials. MedShape’s sports medicine division was acquired by Conmed (NASDAQ:CNMD). Vertera created the first spinal fusion implants based on porous polymer technologies and was acquired by Nuvasive (NASDAQ:NUVA). Restor3d is utilizing 3D printing of polymers and metals to create unique patient-specific, surgeon-designed implants on-demand across multiple fields of medicine.
Dr. Gall is a graduate of the University of Illinois at Urbana Champaign, where he obtained his B.S., M.S., and Ph.D. in Mechanical Engineering.
David Helfet, M.D.
Dr. David Helfet is Chief Emeritus of the Orthopedic Trauma Service (OTS) for the Hospital for Special Surgery and NewYork-Presbyterian Hospital, Professor of Orthopedic Surgery at Weill Medical College of Cornell University, and is annually ranked as one of Castle-Connolly’s “America’s Top Doctors.” Dr. Helfet is a world-renowned orthopedic surgeon and has served as a member of the Board of Directors of Synthes, Chairman of AO Clinical Investigation and Documentation, President of the Orthopaedic Trauma Association, a member of the American Academy of Orthopaedic Surgeons (AAOS), and an examiner of the American Board of Orthopaedic Surgery.
Dr. Helfet is globally published and has received numerous honors, including the Presidential Guest and Watson-Jones Memorial Lecture of the British Orthopaedic Association, the Hospital for Special Surgery Lifetime Achievement Award, and the Inaugural Award of the Society of Honorary Police Surgeons of the City of New York. He was recently inducted into the Johns Hopkins Society of Scholars and is currently designated as the Orthopedic Trauma specialist for the Fire Department of New York (FDNY), the New York Police Department (NYPD), and New York State Police (NYSP).
Dr. Helfet received a BSc in Biochemistry, M.B.CH.B from the University of Cape Town and completed internship at Edendale Hospital in Pietermaritzburg, South Africa. He then went on to complete Surgical and Orthopedic Residencies at Johns Hopkins University; a Trauma Fellowship at the University of Bern/Insel Hospital, in Bern, Switzerland; and a Sports Medicine Fellowship at UCLA.
Frank P. Cammisa, Jr., M.D.
Dr. Frank P. Cammisa, Jr. is Chief Emeritus of the Spine Service at Hospital for Special Surgery, where he specializes in the surgical treatment of spinal disorders. In addition, he is a Professor of Clinical Orthopedic Surgery at Weill Cornell Medical College.
Recognized as a pioneer in the use of innovative surgical techniques, procedures and modalities, Dr. Cammisa’s areas of expertise include minimally-invasive spinal surgery, computer-assisted spinal surgery, microsurgery, athletic spinal injuries, and motion-preserving procedures, including artificial disc replacement. He has been a principal or lead investigator in a number of major research studies and has lectured at hundreds of professional meetings, both nationally and internationally.
A graduate of Tufts University and the College of Physicians and Surgeons at Columbia Presbyterian Medical Center, Dr. Cammisa trained at Hospital for Special Surgery and became a Fellow in Spinal Surgery at the Department of Orthopaedic Surgery and Neurosurgery at The University of Miami. He is a Fellow of the American College of Surgeons, the American Academy of Orthopedic Surgeons, and a Diplomate of the American Board of Orthopedic Surgery, as well as a member of the North American Spine Society, Cervical Spine Research Society, Scoliosis Research Society, International Society for the Study of Lumbar Spine, American Spinal Injury Association and Spine Arthroplasty Society.
Scientific Advisory Board
Celeste Abjornson, Ph.D.
Dr. Celeste Abjornson is the Director of the Integrated Spine Research Program (ISRP) at Hospital for Special Surgery, which was formed in 2009 with the strategic mission of developing and applying novel therapies and technologies to treat chronic degenerative conditions of the spine—by performing basic and translational research to provide better clinical interventions in the future. Through close collaborations with scientists, clinician-scientists, and clinicians, Dr. Abjornson and her research team are performing high-impact research to advance patient care.
The spine laboratories that Dr. Abjornson directs at HSS focus on basic and translational research in three major areas: biologic agents and therapies for spinal surgery, non-fusion technologies, and bioactive coatings. The complementary nature of the research themes between pre-clinical and clinical programs enables the maturation of ideas from concept to clinical practice, with the sole aim of improving patient outcomes.
Dr. Abjornson has authored and co-authored numerous publications and textbook chapters, presenting her research at conferences held domestically and internationally. She earned her bachelor’s and doctorate degrees in Bioengineering and Biomedical Engineering from Vanderbilt and Rutgers Universities, respectively.
Jeffrey Schwartz, Ph.D.
Dr. Jeffrey Schwartz, Ph.D. is the inventor behind Orthobond’s novel platform technology. He has been a Professor of Chemistry at Princeton University for nearly 50 years.
An internationally-recognized expert in surface organometallic and interface chemistry, Dr. Schwartz has authored or co-authored more than 250 scientific publications and holds more than two dozen patents. He has received many prestigious honors and awards over the course of his career, including the President’s Award for Distinguished Teaching in 2012.
In the late 1990s, Dr. Schwartz began working on the technology that would ultimately become the basis for Orthobond. After years of relentless work and innovation, Dr. Schwartz looks forward to seeing Orthobond’s technology commercially available for patients in the US and abroad.
A graduate of M.I.T. and Stanford University, Dr. Schwartz completed his postdoctoral work at Columbia University.
Thomas W. Bauer, M.D., Ph.D.
Dr. Thomas W. Bauer is the Pathologist-in-Chief at the Hospital For Special Surgery’s Department of Pathology and Laboratory Medicine. Prior to fulfilling his current role at HSS, Dr. Bauer practiced from 1983-2017 at the Cleveland Clinic, in the Department of Anatomic Pathology.
Dr. Bauer specializes in non-neoplastic orthopedic pathology, investigating the mechanisms of success and failure of reconstructive orthopedic procedures, devices, and bone graft substitute materials. He is an expert in the optimum use of laboratory tests to diagnose or rule-out periprosthetic infections and is recognized as an early innovator in the application of digital imaging to surgical pathology diagnosis and research.
Dr. Bauer has given more than 200 lectures and has authored or co-authored more than 230 peer-reviewed publications. One of his research publications related to bone graft materials has been cited by other investigators more than 1,000 times. In addition, he has served as a voting member on advisory panels in two different branches of the FDA and has consulted several companies, primarily in the field of orthopedic devices and therapeutics.
Dr. Bauer received his M.D. and Ph.D. degrees from the University of Nebraska Medical Center, before completing an Anatomic and Clinical Pathology residency at The Johns Hopkins Hospital.